Anas M Elgenidy

Dr. Anas M Elgenidy

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2022 in Journal of Renal Nutrition
Verified
Journal Article
Closed access
PDF file
AEAnas M Elgenidy
Anas M Elgenidy
MAMostafa Atef Amin
Mostafa Atef Amin
AAAhmed K. Awad
Ahmed K. Awad
FHFaeq Husain-Syed
Faeq Husain-Syed
MAMostafa G. Aly
Mostafa G. Aly

31 May 2021 in Journal Of Clinical Neurophysiology
Verified
Journal Article
Closed access
RARamy Abdelnaby
Ramy Abdelnaby
MEMohamed Elsayed
Mohamed Elsayed
KMKhaled Mohamed
Khaled Mohamed
KDKhaled T. Dardeer
Khaled T. Dardeer
YSYousef Tarek Sonbol
Yousef Tarek Sonbol
AMAndrea Maier
Andrea Maier
Purpose: To establish the first comprehensive and standardized set of vagus nerve (VN) sonographic reference values across all the published studies that can be used to standardize and guide clinical practice and research. Methods: This systematic review includes all possible available data from a total of 27 studies and 21 of them were included in the meta-analysis having a total of 864 participants. Results: The overall mean cross-sectional area ranged from 2.29 to 2.76 mm2 for the right VN and from 1.83 to 2.23 mm2 for the left VN with 95% confidence interval. Sonographic reference values of VN at common carotid artery bifurcation, thyroid gland, and cartilage as well as other anatomic landmarks were provided. Conclusions: The mean cross-sectional area of the right VN of 2.53 mm2 and the left one of 2.03 mm2 can be considered as sonographic reference values in healthy adults. This review provides these reference values to be considered in the further sonographic evaluation of VNs.

13 September 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
AEAnas M Elgenidy
Anas M Elgenidy
AAAhmed M Afifi
Ahmed M Afifi
PJPrasun Jalal
Prasun Jalal
Background: Intrahepatic cholangiocarcinoma (iCCA) has shown a substantial increase in mortality globally. On the contrary, perihilar cholangiocarcinoma and distal cholangiocarcinoma have been decreasing. We aim to evaluate the causes of death after iCCA diagnosis. Methods: We studied 8,962 patients with iCCA diagnosed between 2000 and 2018 in the United States. The standardized mortality ratio for each cause of death was calculated. We used R software version 3.5 to perform Kaplan–Meier survival tests and covariate-adjusted Cox models. Results: Of the 8,962 patients diagnosed with iCCA, 7,335 (81.8%) died during the follow-up period with a mean age of death of 67.88 years. The highest number of deaths (4,786; 65.2%) occurred within the first year following iCCA diagnosis. 4,832 (66%) were from iCCA, 2,063 (28%) were from other cancers, and 440 (6%) were from non-cancer causes mainly cardiovascular disease. The overall mean survival after 1 year of diagnosis was 40.8% (39.8–41.9); however, the overall mean survival was 9.8% (9–10.5) after 5 years of diagnosis. The multivariable analysis showed that age, sex, stage, and management of iCCA have a statistically significant impact on survival. Conclusions: Following iCCA diagnosis, about 34% died from non-iCCA causes. The most common non-iCCA cancer cause was liver cancer, and cardiovascular disease represents a substantial percentage of non-cancer deaths. Our findings provide insights into how iCCA survivors should be followed up regarding future risks. Impact: The management and follow-up should be tailored to the needs of each patient with iCCA.

9 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
RARamy Abdelnaby
Ramy Abdelnaby
KMKhaled Mohamed
Khaled Mohamed
AEAnas M Elgenidy
Anas M Elgenidy
YSYousef Tarek Sonbol
Yousef Tarek Sonbol
MBMahmoud Bedewy
Mahmoud Bedewy
JZJana Zschuentzsch
Jana Zschuentzsch
Inclusion body myositis (IBM) is a slowly progressive muscle weakness of distal and proximal muscles, which is diagnosed by clinical and histopathological criteria. Imaging biomarkers are inconsistently used and do not follow international standardized criteria. We conducted a systematic review and meta-analysis to investigate the diagnostic value of muscle ultrasound (US) in IBM compared to healthy controls. A systematic search of PubMed/MEDLINE, Scopus and Web of Science was performed. Articles reporting the use of muscle ultrasound in IBM, and published in peer-reviewed journals until 11 September 2021, were included in our study. Seven studies were included, with a total of 108 IBM and 171 healthy controls. Echogenicity between IBM and healthy controls, which was assessed by three studies, demonstrated a significant mean difference in the flexor digitorum profundus (FDP) muscle, which had a grey scale value (GSV) of 36.55 (95% CI, 28.65–44.45, p < 0.001), and in the gastrocnemius (GC), which had a GSV of 27.90 (95% CI 16.32–39.48, p < 0.001). Muscle thickness in the FDP showed no significant difference between the groups. The pooled sensitivity and specificity of US in the differentiation between IBM and the controls were 82% and 98%, respectively, and the area under the curve was 0.612. IBM is a rare disease, which is reflected in the low numbers of patients included in each of the studies and thus there was high heterogeneity in the results. Nevertheless, the selected studies conclusively demonstrated significant differences in echogenicity of the FDP and GC in IBM, compared to controls. Further high-quality studies, using standardized operating procedures, are needed to implement muscle ultrasound in the diagnostic criteria.

31 December 2022 in Muscle & Nerve
Verified
Journal Article
Open access
RARamy Abdelnaby
Ramy Abdelnaby
AEAnas M Elgenidy
Anas M Elgenidy
KMKhaled Mohamed
Khaled Mohamed
YSYousef T. Sonbol
Yousef T. Sonbol
MEMohamed M. Elwshahi
Mohamed M. Elwshahi
MCMichael S. Cartwright
Michael S. Cartwright
Introduction/Aims: Nerve ultrasound is useful in the diagnosis and follow‐up of peripheral nerve disorders in children. The aim of this study was to explore and analyze the current literature on nerve cross‐sectional area (CSA) in healthy children, with the goal of presenting reference values and discussing their implications.Methods: We performed a systematic review and meta‐analysis of studies that reported ultrasound measurements of the upper or lower limb nerves in healthy children through a search of Web of Science, PubMed, Embase, and Scopus.Results: Sixteen studies with measurements of 10 nerves covering a total of 5149 nerves measured in 823 healthy children (445 boys and 378 girls) were included. Mean nerve CSA increased with age in the median nerve at the middle and lower third of the upper arm, mid‐forearm, and distal wrist crease, the ulnar nerve at the middle third of the upper arm and elbow, the radial nerve at the spiral groove, and the tibial nerve at the popliteal fossa. Growth charts for nerve CSA for different age groups were developed.Discussion: This meta‐analysis provides robust reference values for nerve CSA at different sites in children, and this can inform clinical practice and assist in identifying nerve enlargement. Moreover, it identifies the strength and quality of the current published data. We recommend future studies divide their samples into smaller age subgroups and standardize the anatomic site of measurement.

28 October 2022 in Heliyon
Verified
Journal Article
Open access
HCHuzaifa Ahmad Cheema
Huzaifa Ahmad Cheema
MFMaurish Fatima
Maurish Fatima
ASAbia Shahid
Abia Shahid
OBOumnia Bouaddi
Oumnia Bouaddi
AEAnas M Elgenidy
Anas M Elgenidy
KLKa Yiu Lee
Ka Yiu Lee
Previous randomized controlled trials (RCTs) and meta-analyses of RCTs evaluating vitamin D supplementation for the prevention of cancer incidence and mortality have found inconsistent results and no meta-analysis has assessed the quality of the evidence available. We, therefore, aimed to perform an updated meta-analysis by including recent large-scale RCTs and assessing the quality of the pooled evidence. We searched several databases and trial registers from inception to April 2022. We used a random-effects model to estimate pooled risk ratios (RRs) and 95% confidence intervals (CIs). We used the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) considerations to evaluate the certainty of evidence. We included 13 RCTs in our study. Vitamin D supplementation had no effect on the risk of total cancer incidence (RR 0.99, 95% CI: 0.94–1.04; I2= 0%), total cancer mortality (RR 0.93, 95% CI: 0.84–1.03; I2= 24%) and total mortality (RR 0.92, 95% CI: 0.82–1.04; I2= 36%). The overall quality of evidence was high for all outcomes. Vitamin D supplementation is ineffective in reducing total cancer incidence and mortality in largely vitamin D-replete older adult populations. Future research should be based on populations with a higher prevalence of vitamin D deficiency and should involve more extended follow-up periods. PROSPERO database, CRD42021285401.